Milestone Pharmaceuticals... (MIST)
0.75
-0.05 (-6.61%)
At close: Apr 03, 2025, 3:59 PM
0.74
-1.32%
After-hours: Apr 03, 2025, 07:32 PM EDT
-6.61% (1D)
| Bid | 0.7 |
| Market Cap | 40.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.67 |
| PE Ratio (ttm) | -1.12 |
| Forward PE | -2.44 |
| Analyst | Buy |
| Ask | 0.75 |
| Volume | 2,673,231 |
| Avg. Volume (20D) | 2,233,183 |
| Open | 0.78 |
| Previous Close | 0.80 |
| Day's Range | 0.72 - 0.80 |
| 52-Week Range | 0.70 - 2.75 |
| Beta | 1.84 |
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and ...
Industry Biotechnology
Sector Healthcare
IPO Date May 9, 2019
Employees 33
Stock Exchange NASDAQ
Ticker Symbol MIST
Website https://www.milestonepharma.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MIST stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 1165.15% from the latest price.
Stock Forecasts6 days ago
-60.89%
Milestone Pharmaceuticals shares are trading lower...
Unlock content with
Pro Subscription
7 months ago
+2.86%
Milestone Pharmaceuticals shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $9 price target.
